Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 ADME and absolute bioavailability study of PF-06650833 in healthy male volunteers
NL-OMON44374Phase 1Active, not recruiting
- Sponsor
- Pfizer
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of zimlovisertib in rheumatoid arthritis (RA), sponsored by Pfizer. Primary endpoint: Excretion of total radioactivity in urine and feces. Started Dec 2017; status: active, not recruiting.
02
Drugs
zimlovisertib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON44374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44374.